| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.065 | 0.06 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.07 | 0.06 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.07 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.07 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.13 | 0.07 |
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | 0.066 | 0.07 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.07 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.064 | 0.07 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.056 | 0.07 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.07 |